Myriad’s myPath® Melanoma Test Receives Medicare Coverage
Go back to Myriad’s myPath® Melanoma Test Receives Medicare Coverage| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 2.87 -0.18 (5.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.05 | 52 Week High | $45.34 | |||
| Open | $3.01 | 52 Week Low | $15.92 | |||
| Day High | $3.01 | P/E | 1.23 | |||
| Day Low | $2.84 | EPS | $2.33 | |||
| Volume | 2,041,074 | |||||
